Simplify diabetes management for your patients
Omnipod® 5 Automated Insulin Delivery
The first wearable, tubeless, hybrid closed loop system that integrates with the leading sensor brands∞, for your patients with type 1 diabetes (T1D) aged 2 years and older.
Now CE marked, UKCA marked and compatible with the leading sensor brands**
- Your patients can experience the freedom of automated insulin delivery with their preferred glucose sensor
- SmartAdjust™ Technology adjusts basal insulin delivery, every five minutes, so you don’t have to. ** It proactively helps to correct highs and protect from lows.1,2
- Improved HbA1c and time in range across age groups vs prior therapy, while time in hypoglycaemia remained low1,2
The System
Controller + Pod + Sensor
The Algorithm Explained
SmartAdjust™ Technology
SmartAdjust™ technology adjusts basal insulin automatically No need to continuously fine-tune basal settings. The system uses recent total daily insulin history to adapt to changes throughout life like changes in weight, growth and aging.** Watch this short video to learn more about the technology and how it works.
Want to get a hands-on understanding of our intuitive Omnipod 5 AID system?
Try the free simulator app on your smartphone.
We believe in freedom of choice
For people with type 1 diabetes, we know that choosing an insulin pump for the first time or changing from an existing one is not an easy option
We are also aware that four-year warranties on insulin pumps are typically viewed as ‘lock-in’ periods and a potential barrier to patient choice.
That is why we strive to take steps to facilitate flexibility and reduce ‘lock-in’ periods with the Omnipod DASH® and Omnipod® 5 System.
The actual steps we take may vary by location, to understand more on how we do this contact your local Omnipod® Representative or request a call-back.
The Omnipod DASH® System
Help your patients manage T1D with an easy-to-use insulin delivery system and support them in improving glycaemic control.*3
View this short video to find out more about Pod Therapy and learn how the Omnipod DASH® Insulin Management System could benefit your patients.
Arrange a meeting with an Omnipod® representative
Do you have questions about Omnipod? Our team is happy to provide you with the information you need and help you to determine which of your patients could best benefit from Omnipod.
(ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as
measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, P<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), P<0.0001). Mean time in hypoglycaemic range in
adults/adolescents (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3-mo Omnipod 5 = 1.32%, P<0.0
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-
daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5
use:7.4% vs 6.9% or 57 mmol/ml vs. 53 mmol/mol; (P<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo
Omnipod 5: 5
3. Aleppo G et al. Diabetes Ther. (2023). Retrospective observational study of 4,738 people with T1D in the US before (baseline) and 90 days after (follow-up)
initiation of the tubeless Omnipod DASH Insulin Management System, children, adolescents and adults who switched from MDI to Omnipod saw an improvement
in HbA1c of -0.9% (8.6 to 7.7% for pediatric participants and 8.5% to 7.6% for adults); Pediatric self-reported hypoglycemia episodes/week improved - 1.3 (2.8 to
1.5) and adult hypoglycemia improved - 1.6 (2.9 to 1.3). All results had p-value <0.0001.
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1
diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with
NovoLog®/NovoRapid®, Humalog®, Trurapi®/Truvelog®/Insulin aspart Sanofi®, Kirsty®, and Admelog/Insulin lispro Sanofi U-100 insulin.
Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications,
contraindications, warnings, cautions, and instructions.
The Omnipod DASH® Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in
persons requiring insulin. Additionally, the Omnipod DASH® System is interoperable with a compatible blood glucose meter to receive and display blood glucose
measurements. The Omnipod DASH® System has been tested and found to be safe for use with the following U-100 insulin: NovoLog®, Humalog®, Apidra®, Fiasp®, Lyumjev®,
or Admelog®. Refer to Omnipod DASH® Insulin Management System User Guide and www.omnipod.com/safety for complete safety information including indications,
contraindications, warnings, cautions, and instructions.